- Home
- SOPH vs INBX Comparison
SOPH vs INBX Comparison
Compare SOPH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | INBX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 1.4B |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SOPH | INBX |
|---|---|---|
| Price | $6.40 | $85.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.50 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 387.6K | 326.1K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $2.92 | $20.55 |
| 52 Week High | $6.74 | $155.29 |
Technical Indicators
Market Signals| Indicator | SOPH | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 68.45 | 40.32 |
| Support Level | $4.63 | $85.94 |
| Resistance Level | N/A | $96.12 |
| Average True Range (ATR) | 0.37 | 6.15 |
| MACD | 0.07 | -0.84 |
| Stochastic Oscillator | 79.12 | 15.68 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.